Divi's Laboratories (NSE:DIVISLAB) Cyclically Adjusted Revenue per Share: ₹332.86 (As of Mar. 2026)


NSE:DIVISLAB Divi's Laboratories Ltd NSE:DIVISLAB
94 GF Score
Price ₹6,757.00
GF Value ₹6,755.55
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Divi's Laboratories Cyclically Adjusted Revenue per Share?

Divi's Laboratories NSE:DIVISLAB +1.11% 94 Cyclically Adjusted Revenue per Share is ₹332.86 as of Mar. 2026. GuruFocus rates NSE:DIVISLAB with a GF Score™ of 94/100 and a GF Value™ of ₹6,755.55 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Divi's Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was ₹106.719. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹332.86 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Divi's Laboratories's average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-04), Divi's Laboratories's current stock price is ₹6757.00. Divi's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹332.86. Divi's Laboratories's Cyclically Adjusted PS Ratio of today is 20.30.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Divi's Laboratories was 21.87. The lowest was 17.59. And the median was 19.54.


Divi's Laboratories  (NSE:DIVISLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Divi's Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6757.00/332.86
=20.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Divi's Laboratories was 21.87. The lowest was 17.59. And the median was 19.54.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Divi's Laboratories Cyclically Adjusted Revenue per Share Related Terms


Divi's Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Divi's Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Divi's Laboratories Cyclically Adjusted Revenue per Share Chart

Divi's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 309.74 332.86

Divi's Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 309.74 315.73 323.70 327.84 332.86

NSE:DIVISLAB vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's Cyclically Adjusted PS Ratio falls into.


NSE:DIVISLAB
94GF Score
Divi's Laboratories Ltd NSE:DIVISLAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Divi's Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Divi's Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=106.719/164.2724*164.2724
=106.719

Current CPI (Mar. 2026) = 164.2724.

Divi's Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201103 0.000 70.768 0.000
201203 0.000 76.889 0.000
201303 0.000 85.687 0.000
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 37.479 111.317 55.309
201809 49.878 115.142 71.161
201812 51.237 115.142 73.100
201903 42.361 118.202 58.872
201906 43.794 120.880 59.515
201909 54.455 123.175 72.624
201912 52.609 126.235 68.461
202003 48.456 124.705 63.830
202006 65.201 127.000 84.336
202009 65.886 130.118 83.180
202012 64.100 130.889 80.449
202103 63.163 131.771 78.742
202106 73.870 134.084 90.501
202109 74.852 135.847 90.514
202112 93.928 138.161 111.680
202203 88.810 138.822 105.092
202206 84.932 142.347 98.014
202209 69.986 144.661 79.474
202212 64.524 145.763 72.718
202303 69.536 146.865 77.778
202306 66.975 150.280 73.211
202309 71.917 151.492 77.984
202312 69.951 152.924 75.142
202403 84.810 153.035 91.038
202406 79.794 155.789 84.139
202409 88.019 157.882 91.582
202412 87.406 158.323 90.691
202503 97.347 157.552 101.500
202506 90.607 159.755 93.169
202509 102.335 162.289 103.586
202512 98.175 163.281 98.771
202603 106.719 164.272 106.719

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹332.86 mean?
Divi's Laboratories (NSE:DIVISLAB) has a Cyclically Adjusted Revenue per Share of ₹332.86 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Divi's Laboratories and its competitors.
Is Divi's Laboratories' Cyclically Adjusted Revenue per Share too high?
Divi's Laboratories' current Cyclically Adjusted Revenue per Share is ₹332.86. Overall, Divi's Laboratories has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Divi's Laboratories' Cyclically Adjusted Revenue per Share of ₹332.86 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Divi's Laboratories and its competitors. Divi's Laboratories's current Cyclically Adjusted Revenue per Share is ₹332.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,755.55, compared to a current price of ₹6,757.00 — trading 0% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹332.86. Divi's Laboratories' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current Cyclically Adjusted Revenue per Share is ₹332.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued. The current stock price of ₹6,757.00 is trading 0% above its estimated GF Value™ of ₹6,755.55. GuruFocus considers Divi's Laboratories to be Fairly Valued.

Key valuation signals for NSE:DIVISLAB:

  • Cyclically Adjusted Revenue per Share: ₹332.86
  • GF Value™: ₹6,755.55 vs. price of ₹6,757.00 (0% above fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Divi's Laboratories Business Description

Other Exchanges 532488:India
Address Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
94GF Score

Get the complete analysis for NSE:DIVISLAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6,757.00
Price
₹6,755.55
GF Value